The new vaccines: Building viruses that elicit antitumor immunity

被引：59

作者：

Restifo, NP

机构：

[1] Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892

来源：

CURRENT OPINION IN IMMUNOLOGY | 1996年 / 8卷 / 05期

关键词：

D O I：

10.1016/S0952-7915(96)80082-3

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Whereas cancer cells are poor immunogens, some viruses are capable of eliciting powerful and lifelong immunity. Recombinant viruses and plasmid DNA encoding tumor-associated antigens can elicit powerful and specific immune responses that can be enhanced by the use of cytokines and costimulatory molecules. These immune responses have destroyed growing tumor cells in experimental animal models. For the first time, immunotherapeutic strategies that employ recombinant viruses are being tested in clinical trials with cancer patients.

引用

页码：658 / 663

页数：6

共 54 条

[1]

Abrams SI, 1996, SEMIN ONCOL, V23, P118

[2] PEPTIDE-SPECIFIC ACTIVATION OF CYTOLYTIC CD4(+) T-LYMPHOCYTES AGAINST TUMOR-CELLS BEARING MUTATED EPITOPES OF K-RAS P21 [J].